Franklin Genomic Advancements ETF (HELX) Stock Price, Quote, News & History

Comments

Franklin Genomic Advancements ETF (HELX) Stock Price, Quote, News & History

HELXBATS

Trade with Public

Price data is not available

OverviewNews Holdings Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Sector

Healthcare

Region

AUM

21.73M

Fund Score

Key Statistics

Open

High

52 Wk High

$38.17

AUM

21.73M

Dividend

$0.14

Ex-Div Date

Dec 30, 2025

Volume

Market Cap

$42.13B

Mgmt Fee

0.5%

P/E Ratio

28.14

Prev. Close

$34.59

Low

52 Wk Low

$24.94

Shares Out

300.00K

Yield

0.41%

Div. Freq

Avg. Volume Daily

1.29K

Beta

1.09

Avg. Expense Ratio

0.5%

P/B Ratio

4.44

Recent Franklin Genomic Advancements ETF News

Why Is Medpace Stock Diving On Tuesday?

Medpace Holdings reports Q3 results with revenue of $533.3M, below consensus. Backlog and EBITDA increased. Medspace lowered its FY24 revenue forecast.

Lekha Gupta

FAQ

How do I buy Franklin Genomic Advancements ETF (HELX) stock?

You can purchase shares of Franklin Genomic Advancements ETF (BATS:HELX) through any online brokerage.

View our list of the best stock brokerages

Who are Franklin Genomic Advancements ETF (HELX) competitors?

There are no as such competitors for Franklin Genomic Advancements ETF.

What is the forecast, or price target, for Franklin Genomic Advancements ETF (HELX) stock?

There is no analysis for Franklin Genomic Advancements ETF to provide a consensus price target.

What is the current price for Franklin Genomic Advancements ETF (HELX)?

The stock price for Franklin Genomic Advancements ETF (BATS: HELX) is $ last updated December 31, 1969 at 7:00 PM EST.

Does Franklin Genomic Advancements ETF (HELX) pay a dividend?

There are no upcoming dividends for Franklin Genomic Advancements ETF.

When is Franklin Genomic Advancements ETF (BATS:HELX) reporting earnings?

Franklin Genomic Advancements ETF does not have any upcoming earnings scheduled.

Is Franklin Genomic Advancements ETF (HELX) going to split?

There is no upcoming split for Franklin Genomic Advancements ETF.

Key Statistics

Open

High

52 Wk High

$38.17

AUM

21.73M

Dividend

$0.14

Ex-Div Date

Dec 30, 2025

Volume

Market Cap

$42.13B

Mgmt Fee

0.5%

P/E Ratio

28.14

Prev. Close

$34.59

Low

52 Wk Low

$24.94

Shares Out

300.00K

Yield

0.41%

Div. Freq

Avg. Volume Daily

1.29K

Beta

1.09

Avg. Expense Ratio

0.5%

P/B Ratio

4.44

About

Sector

N/A

Industry

N/A

ETF Details

Sector	Healthcare
Category	High Performer-High Growth
Investment Style	Mid Cap Growth
Fund Inception	Feb 25, 2020
Managers	Matthew J. Moberg
Definition	An equity fund portfolio full of stocks with both strong financial performance and superior growth potential

Investment Policy

The Fund invests in equity securities inside and outside of the United States, including developing or emerging markets.

Top ETF Holdings

Symbol	Name	Share %
KRYS	Krystal Biotech Inc	5.25%
NTRA	Natera Inc	6.72%
UTHR	United Therapeutics Co...	4.08%
GH	Guardant Health Inc	6.58%
INSM	Insmed Inc	3.90%
ADPT	Adaptive Biotechnologi...	3.31%
BBIO	Bridgebio Pharma Inc	3.67%
KR	Samsung Biologics Co L...	3.16%
LGND	Ligand Pharmaceuticals...	3.63%
LN	Astrazeneca Plc, ADR	3.21%

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Sector

Healthcare

Region

AUM

21.73M

Fund Score

Key Statistics

Open

High

52 Wk High

$38.17

AUM

21.73M

Dividend

$0.14

Ex-Div Date

Dec 30, 2025

Volume

Market Cap

$42.13B

Mgmt Fee

0.5%

P/E Ratio

28.14

Prev. Close

$34.59

Low

52 Wk Low

$24.94

Shares Out

300.00K

Yield

0.41%

Div. Freq

Avg. Volume Daily

1.29K

Beta

1.09

Avg. Expense Ratio

0.5%

P/B Ratio

4.44

Recent Franklin Genomic Advancements ETF News

Why Is Medpace Stock Diving On Tuesday?

Medpace Holdings reports Q3 results with revenue of $533.3M, below consensus. Backlog and EBITDA increased. Medspace lowered its FY24 revenue forecast.

Lekha Gupta

FAQ

How do I buy Franklin Genomic Advancements ETF (HELX) stock?

You can purchase shares of Franklin Genomic Advancements ETF (BATS:HELX) through any online brokerage.

View our list of the best stock brokerages

Who are Franklin Genomic Advancements ETF (HELX) competitors?

There are no as such competitors for Franklin Genomic Advancements ETF.

What is the forecast, or price target, for Franklin Genomic Advancements ETF (HELX) stock?

There is no analysis for Franklin Genomic Advancements ETF to provide a consensus price target.

What is the current price for Franklin Genomic Advancements ETF (HELX)?

The stock price for Franklin Genomic Advancements ETF (BATS: HELX) is $ last updated December 31, 1969 at 7:00 PM EST.

Does Franklin Genomic Advancements ETF (HELX) pay a dividend?

There are no upcoming dividends for Franklin Genomic Advancements ETF.

When is Franklin Genomic Advancements ETF (BATS:HELX) reporting earnings?

Franklin Genomic Advancements ETF does not have any upcoming earnings scheduled.

Is Franklin Genomic Advancements ETF (HELX) going to split?

There is no upcoming split for Franklin Genomic Advancements ETF.

Key Statistics

Open

High

52 Wk High

$38.17

AUM

21.73M

Dividend

$0.14

Ex-Div Date

Dec 30, 2025

Volume

Market Cap

$42.13B

Mgmt Fee

0.5%

P/E Ratio

28.14

Prev. Close

$34.59

Low

52 Wk Low

$24.94

Shares Out

300.00K

Yield

0.41%

Div. Freq

Avg. Volume Daily

1.29K

Beta

1.09

Avg. Expense Ratio

0.5%

P/B Ratio

4.44

About

Sector

N/A

Industry

N/A

ETF Details

Sector	Healthcare
Category	High Performer-High Growth
Investment Style	Mid Cap Growth
Fund Inception	Feb 25, 2020
Managers	Matthew J. Moberg
Definition	An equity fund portfolio full of stocks with both strong financial performance and superior growth potential

Investment Policy

The Fund invests in equity securities inside and outside of the United States, including developing or emerging markets.

Top ETF Holdings

Symbol	Name	Share %
KRYS	Krystal Biotech Inc	5.25%
NTRA	Natera Inc	6.72%
UTHR	United Therapeutics Co...	4.08%
GH	Guardant Health Inc	6.58%
INSM	Insmed Inc	3.90%
ADPT	Adaptive Biotechnologi...	3.31%
BBIO	Bridgebio Pharma Inc	3.67%
KR	Samsung Biologics Co L...	3.16%
LGND	Ligand Pharmaceuticals...	3.63%
LN	Astrazeneca Plc, ADR	3.21%